Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-10-10 | Tigenix (Belgium) Finnish Red Cross Blood Service (Finland) | ChondroCelect® | single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults with or without concomitant asymptomatic cartilage lesions (ICRS grade I or II). |
distribution |
Rheumatic diseases | Distribution agreement |
2011-10-10 | Exonhit (France) Pfizer (USA - NY) | Alzheimer’s disease biomarkers | Alzheimer’s disease | R&D |
Neurodegenerative diseases | R&D agreement |
2011-10-06 | Boehringer Ingelheim (Germany) Gilead (USA) | non-catalytic site integrase inhibitors (NCINIs) for HIV | HIV-AIDS | licensing |
Infectious diseases | Licensing agreement |
2011-10-06 | Redbiotech (Switzerland) Merck&co (USA) | technology platform rePAX™ | undisclosed | R&D |
undisclosed | R&D agreement |
2011-10-05 | Bavarian Nordic (Denmark) National Cancer Institute (USA) | new off-the-shelf product candidates for the treatment of multiple cancers and a new technology platform based on NCI\\\'s cancer vaccine technology | research - R&D - licensing | Cancer - Oncology | R&D agreement | |
2011-10-05 | Evotec (Germany) UCB (Belgium) | research - R&D | Immunology | R&D agreement | ||
2011-10-04 | Vivalis (France) Delta-Vir (Germany) | Newcastle Disease Virus (NDV) produced on Vivalis EB66® cell line | commercialisation |
Cancer - Oncology - Infectious diseases | Production agreement | |
2011-10-03 | Warnex (Canada) Decode Genetics (Iceland) | 10 deCODE Genetics\' DNA-based tests for assessing the risk of developing certain common diseases. | distribution |
Cancer Oncology Cardiovascular diseases Ophtalmological diseaes | Distribution agreement | |
2011-10-03 | Merck KGaA, Merck Serono (Germany) Ono Pharmaceutical (Japan) | Stimuvax® (BLP25 liposome vaccine) | non-small cell lung cancer | licensing |
Cancer - Oncology | Licensing agreement |
2011-09-29 | Almirall (Spain) Nycomed (Switzerland) | ebastine (Kestine®) | allergic rhinitis, chronic idiopathic urticaria | licensing |
Allergic diseases - Dermatological diseases - Immunological diseases | Licensing agreement |
2011-09-29 | Lundbeck (Denmark) Proximagen (UK) | novel innovative therapies for serious diseases such as epilepsy, pain and inflammatory disorders | serious diseases such as epilepsy, pain and inflammatory disorders | R&D |
CNS diseases - Inflammatory diseases - Neurological diseases | R&D agreement |
2011-09-27 | Hypha Discovery (UK) Ferrer Grupo (Spain) | low molecular weight natural products to treat microbial infections | microbial infections | R&D |
Infectious diseases | R&D agreement |
2011-09-27 | Lonza (Switzerland) Mesoblast (Australia) | adult stem cell products | manufacturing |
Regenerative medicine | Production agreement | |
2011-09-27 | Silence Therapeutics (UK) undisclosed top 10 pharma company | DACC formulated siRNAs | undisclosed | R&D |
R&D agreement | |
2011-09-25 | Biotec Pharmacon (Norway) Affymetrix (USA) | shrimp alkaline phosphatase | Supply |
Services contract | ||
2011-09-22 | Almirall (Spain) Proteros biostructures (Germany) | small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases | inflammatory diseases | R&D |
Inflammatory diseases | R&D agreement |
2011-09-21 | Sanofi Pasteur (France) University of California, San Diego (USA) | acne vaccine and treatment | Acne vulgaris | R&D |
Dermatological diseases - Infectious diseases | R&D agreement |
2011-09-21 | CMC Biologics (Denmark-USA) Inspiration Biopharmaceuticals (USA) | IB1001 (intravenous recombinant factor IX (rFIX) product) | treatment and prevention of bleeding in individuals with hemophilia B | manufacturing |
Hematological diseases - Genetic diseases - Rare diseases | Production agreement |
2011-09-19 | Merck KGaA, Merck Serono (Germany) Peptimmune (USA) | PI-2301 | mutliple sclerosis | licensing |
Neurodegenerative diseases - Autoimmune diseases | Licensing agreement |
2011-09-19 | NeuroVive Pharmaceutical (Sweden) Selvia (UK) | new medicines and drug compounds targeting mitochondrial physiology and pathophysiology | R&D |